NDAC meetings
This article was originally published in The Tan Sheet
Executive Summary
Nonprescription drugs advisory panel will meet jointly with the Dermatologic & Ophthalmic committee to "discuss what should be the necessary and sufficient safety database in order to evaluate the [Rx-to-OTC] switch of topical corticosteroids, especially the database to evaluate the potential for hypothalamic, pituitary, adrenal (HPA) and growth suppression and other systemic and local adverse reactions." The committee will convene at the Washington D.C. Hilton on March 24 from 8 am-5:30 pm, with the hour between 1 pm-2 pm reserved for public comment. NDAC will hold a separate meeting on March 23 to evaluate "microbiologic surrogate endpoints used to demonstrate the effectiveness of antiseptic products used in health care settings"...